Available Online at www.ijpba.in

International Journal of Pharmaceutical and Biological Science Archive 1 (1) 2013, 15-17

SHORT COMMUNICATION ARTICLE

# A NEW SKYLINE FOR EPIGENETIC TREATMENT

**Pramod Khatri**

[1]Genetics Division, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi 110029, India

**Received 10 May 2013; Revised 15 May 2013; Accepted 30 May 2013**

**ABSTRACT**

Histone lysine demethylases are chromatin modifiers which play important roles in numerous pathological procedures for example inflammation and tumor, making them possibly alluring drug targets. In a latest study, Kruidenier et al. gave verification of concept by recognizing chemical matters that hinder demethylation interceded by the two identified histone H3 lysine 27 demethylases, KDM6A and 6B (UTX and JMJD3). The KDM6 inhibitor shows amazing substrate selectivity and can hinder transcription of a plenty of pro-inflammatory genes in cell culture by modifying H3K27me3 level at a portion of the KDM6 target genes.

**KEY WORDS:** KDM6A, H3K27

## INTRODUCTION:

In eukaryotic units, DNA is bundled into chromatin whose fundamental units are nucleosomes. A nucleosome is comprised of 147 bp nucleotides enfolded around a histone octamer, which is made out of two duplicates each of histone H2A, H2B, H3 and H4. Both DNA and histones are imperiled to covalent chemical changes, which influence chromatin organization and role. Latest mass spectrometry investigation documented more than twelve distinctive types of post-translational alterations on histone tails [1]. Around them, lysine methylation was amongst the most broadly studied modifications , incorporating histone H3 lysine 4 (H3K4), H3K9, H3K27, H3K36 and H4K20.

Methylation at the aforementioned lysine buildups has been indicated to play a role in translation, DNA recombination & repair. Histone methylation is controlled by a plenty of methyltransferases & demethylases, which collectively manage histone methylation flow. Histone demethylases are made of two classes, the flavin-dependent amine oxidases and iron-and α-ketoglutarate-dependent dioxygenases, which offer the remarkably identified Jumonji (Jmj) C catalytic domain [2]. The latter class is made out of ~20 affirmed demethylases, which target diverse methylated lysine buildups on histones [2]. Critically, typical human hereditary studies and additionally recent sequencing deliberations of human disease genomes fueled by cutting edge DNA sequencing distinguished potential causal transformations in various chromatin altering enzymes, including histone methyltransferases and demethylases [3-7]. The aforementioned findings raise the thrilling probability that focusing on chromatin-altering compounds may be a fascinating intends to battle human infections.

H3K27 methylation is intervened by the Polycomb Repressive Complex 2 (PRC2), which is a multi-part enzymatic complex with EZH2 being the synergist subunit. H3K27 tri-and di-methylation is inverted by a subfamily of two identified JmjC domain-holding histone demethylases, UTX and JMJD3 (KDM6A and 6B) [2]. H3K27 di-methylation can moreover be demethylated by an additional identified JmjC domain-holding demethylase KIAA1718 (KDM7A) [2]. H3K27 methylation has been demonstrated to play imperative roles in development and separation. H3K27me3 plays a discriminating part in the regulation of the Hox genes, which control animal front-back growth. Steadily, misfortune of the H3K27me3 demethylase UTX brings about a noteworthy back development defect in zebra fish [8]. In embryonic stem cell, H3K27 and H3K4 trimethylation coincide and structure what is known as "bivalent domains" on a subset of basic separation-specific genes. The bivalent dominions are thought to balance genes for activation according to suitable developmental and separation prompts. The resolution of the bivalent domain is prone to be interceded by the H3K4 and H3K27 histone demethylases, respectively.

When H3K27 trimethylation regulation goes off, disease follow. Case in point, overexpression of the H3K27 trimethyl methylase EZH2 is one of the emblems of prostate and breast tumor [9, 10]. Progressively latest studies moreover distinguished activating mutations of EZH2 in follicular lymphoma & diffuse large B cell



*Corresponding author: Pramod Khatri | Email: pramodsinghkhatri@gmail.com

lymphoma [7, 11]. Constantly, somatic transformations of the H3K27me3 demethylase UTX have been recognized in various cancer types [3, 5, 6]. The aforementioned discoveries show the criticalness of this imprint and also the comparing methyltransferase EZH2 and the UTX/JMJD3 demethylases in tumorigenesis.

In addition to cancer disease, H3K27 methylation has moreover been offered evidently in inflammatory reaction. infact, one of the first reports recognizing JMJD3 as a histone H3K27me3 demethylase recorded a quick JMJD3 instigation by proinflammatory stimuli [12], and a follow-up study indicates that JMJD3 is selected to the transcription start sites (TSS) of the larger part of lipopolysaccharide (LPS)-affected genes [13]. The aforementioned studies prescribe that adjusting JMJD3 demethylase movement by minor particles may be restricted to reduce inflammation. however, this probability is entangled by various components. To begin with, the follow-up study proposes that regulation of the proinflammatory genes by JMJD3 may be autonomous of its demethylase action [13]. Second, given the level of sequence similarity right around the JmjC domain of histone demethylases, it was misty if it is practical to produce small molecules with sufficient substrate specificity. Presently both of the aforementioned issues have been replied by a latest study by Kruidenier, Lee, Wilson and collegues [14].

Kruidenier and associates consolidated high-throughput screens with structure-guided configuration to recognize chemical compound that explicitly inhibit the JMJD3 demethylase movement. They screened a ~2 million GSK compound library & acquired various feeble hits. In parallel, they created co-crystals of the JmjC domain in addition to the adjacent GATA-like zinc finger with the H3K27 tri-methylated peptide. A 2.5 Å co-crystal structure permitted them to define the contact destinations on both the histone peptide and the reactant domain. Leveraging the co-crystal structure informative data, the author optimized the starting hits and were ready to acquire a moderately intense lead compound GSK-J1, which has a half-maximum inhibitory concentration of 60 nM.

Further efforts at depicting the co-crystal structure of the JMJD3 synergist domain bound by GSK-J1 exposed the discriminating contact sites of GSK-J1 inside the reactant domain, which helped demarcate the inhibitory mechanism of GSK-J1, i.e., it is hostile with the co-factor α-ketoglutarate however not the substrate. The JMJD3 synergist domain and GSK-J1 co-crystal structure moreover prescribed techniques to alter GSK-J1 for immobilization. The altered compound, GSK-J3, might be joined to sepharose beads without losing its activity. This effects in a KDM6 test, which was then used to catch endogenous JMJD3. In this trial, the author recognized that the immobilized GSK-J3 test pulled down just JMJD3 from phorbol myristate acetate derivation HL-60 monocytic cells, again demonstrating specificity of this compound. however, GSK-J3 moreover can pull down the identified enzyme UTX, prescribing that this compound does not recognize JMJD3 from its identified enzyme UTX.

Imperatively, GSK-J1 indicated no action towards various different demethylases for example the H3K9/K36 demethylases JMJD2A-E, and in addition 60 chromatin regulator incorporating histone deacetylases and 100 kinases. Ever more could be studied concerning the specificity of GSK-J1 when supplemental JmjC demethylases are incorporated in the specificity panel in near future, specifically KIAA1718 (KDM7A), which demethylates H3K27me1/2 [2]. Notwithstanding, the present information prescribe impressive substrate selectivity of GSK-J1, particularly thinking about the elevated level of arrangement homology around JmjC domain of diverse subfamilies of demethylases. Significantly, this finding shows that particular chemical inhibitors might be distinguished for particular subfamilies of demethylases, although it may prove difficult to develop chemical matters that can recognize parts of the same subfamily (for example JMJD3 and UTX).

As conversed earlier, JMJD3 has been demonstrated to play a part in the inflammatory reaction. Intriguingly, a progressively latest study by De Santa et al. recognized that in the LPS-treated macrophages, even though JMJD3 ties to the TSS of numerous targets, the greater part of them have no noticeable H3K27me3 [13]. On certain genes, the H3K27me3 level did go down according to LPS stimulation, yet it was thought to be because of nucleosome depletion [13]. Interestingly, when Kruidenier and colleagues connected the cell permeable form of GSK-J1, i.e., GSK-J4, to LPS-stimulated human primary macrophages, they recognized that GSK-J4 hindered 16 of 34 LPS-induced cytokines. They further exhibited that the inhibitory impact on one of the aforementioned cytokines, TNF-α, might be imitated just when both JMJD3 and UTX were hindered by RNAi, demonstrating that both enzyme are included in the TNF-α generation. This finding support the idea, which was developed based on the pull-down result, that GSK-J4 hinders the action of both JMJD3 and UTX.

Moreover, chromatin immune-precipitation examination demonstrates that the inhibitor prevented the LPS-induced H3K27me3 loss on the TNFA TSS. Together, the aforementioned outcomes exhibit that the demethylase activity of JMJD3 and UTX is needed for their roles in the inflammatory reaction. In the De Santa study [13], admitting that TNFA was bound by JMJD3, it was not



 

on the record of the H3K27me3-enriched genes before LPS stimulation, which might be because of H3K27me3 epitope covering. A progressively latest study supports the significance of the JMJD3 demethylase activity in directing the expression of a subset of its direct target genes [15].

In Summary, the development of KDM6-specific chemical inhibitors by Kruidenier et al shows that it is conceivable to produce subfamily membrane specific demethylase inhibitors, in this way making ready for the hunt for inhibitors of other subfamily membrane, some of which have been showed to play roles in other human infections for example cancer disease. Likewise, the availability of particular chemical inhibitors additionally enables mechanistic investigation as decently showed in this study where the inhibitors were utilized successfully to show the imperativeness of JMJD3/ UTX-mediated demethylation in the inflammatory reaction.

**COMPETING INTERESTS:**

The authors declare that they have no competing interests

**REFERENCES:**


1. Tan M, Luo H, Lee S, *et al*. Cell 2011; 146:1016–1028.
2. Greer EL, Shi Y. Nat Rev Genet 2012; 13:343–357.
3. van Haaften G, Dalgliesh GL, Davies H, *et al*. Nat Genet 2009; 521–523.
4. Dalgliesh GL, Furge K, Greenman C, *et al*. Nature 2010; 463:360–363.
5. Gui Y, Guo G, Huang Y, *et al*. Nat Genet 2011; 43:875–878.
6. Grasso CS, Wu YM, Robinson DR, *et al*. Nature 2012; 487:239–243.
7. Morin RD, Johnson NA, Severson TM, *et al*. Nat Genet 2010; 42:181–185.
8. Lan F, Bayliss PE, Rinn JL, *et al*. Nature 2007; 449:689–694.
9. Varambally S, Dhanasekaran SM, Zhou M, *et al*. Nature 2002; 624–629.
10. Kleer CG, Cao Q, Varambally S, *et al*. Proc Natl Acad Sci USA 2003; 100:11606–11611.
11. Yap DB, Chu J, Berg T, *et al*. Blood 2011; 117:2451–2459
12. De Santa F, Totaro MG, Prosperini E, *et al*. Cell 2007; 130:1083–1094.
13. De Santa F, Narang V, Yap ZH, *et al*. EMBO J 2009; 28:3341–3352.
14. Kruidenier L, Chung CW, Cheng Z, *et al*. Nature 2012; 488:404–408.
15. Chen S, Ma J, Wu F, *et al*. Genes Dev 2012; 26:1364–1375.




 